Wealthspire Advisors LLC boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 120.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 5,362 shares of the company’s stock after purchasing an additional 2,930 shares during the period. Wealthspire Advisors LLC’s holdings in IDEXX Laboratories were worth $2,612,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Nordea Investment Management AB lifted its position in shares of IDEXX Laboratories by 15.5% in the first quarter. Nordea Investment Management AB now owns 13,719 shares of the company’s stock valued at $7,447,000 after buying an additional 1,839 shares during the last quarter. Manning & Napier Advisors LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter valued at $20,418,000. Brevan Howard Capital Management LP acquired a new stake in IDEXX Laboratories during the 4th quarter valued at $3,183,000. First Hawaiian Bank bought a new position in IDEXX Laboratories during the first quarter worth $982,000. Finally, Meyer Handelman Co. acquired a new position in shares of IDEXX Laboratories in the first quarter valued at $2,155,000. Institutional investors own 87.84% of the company’s stock.
IDEXX Laboratories Trading Up 0.7 %
Shares of IDXX stock opened at $500.55 on Friday. The stock has a market cap of $41.20 billion, a P/E ratio of 48.46, a price-to-earnings-growth ratio of 4.17 and a beta of 1.33. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33. The stock has a 50 day simple moving average of $481.18 and a 200 day simple moving average of $501.22.
Analysts Set New Price Targets
IDXX has been the subject of a number of research reports. BTIG Research assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 target price for the company. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a research report on Wednesday, August 14th. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research report on Monday, June 24th. Finally, StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $582.25.
View Our Latest Stock Report on IDXX
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Articles
- Five stocks we like better than IDEXX Laboratories
- The 3 Best Fintech Stocks to Buy Now
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- Pros And Cons Of Monthly Dividend Stocks
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- What is MarketRank™? How to Use it
- MarketBeat Week in Review – 9/9 – 9/13
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.